Swiss dental startup vVardis Holding AG expects to raise $229 million in an IPO in the United States. This is reported in a vVardis press release.
vVardis, whose investors include Apollo Global Management Inc. and OrbiMed Advisors, intends to place 9.5 million shares at a price of $21-24 per share with a total asset value of $4.4 billion.
Goldman Sachs Group Inc. and JPMorgan Chase & Co. are acting as organizers of the stock offering on the New York Stock Exchange.
The vVardis proposal added to the list of companies that concluded deals in the healthcare sector in 2026 (excluding biotechnology and pharmaceuticals) and raised a total of $1.4 billion.
The flagship product of vVardis is a drug for the treatment of caries at an early stage without the need for drilling. Curodont products have been sold to more than 20,000 dental clinics since their launch in the United States in 2024. The bulk of vVardis' revenue comes from the drug Curodont Repair Fluoride Plus.
vVardis will continue to sell Curodont through distributors, including Henry Schein, exclusively in the United States. The company's investors include Cerebro Equity and Heartland Dental, controlled by KKR&Co.
vVardis Holding AG is a Swiss holding company for the development and production of innovative solutions for the dental sector. The headquarters is located in Zug (Switzerland).
Read our Telegram channel "Mergers and acquisitions. AK&M».
Our channel at MAX is "Mergers and Acquisitions. AK&M».
